The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
A. R. Tan
No relevant relationships to disclose
D. Toppmeyer
No relevant relationships to disclose
M. N. Stein
No relevant relationships to disclose
R. A. Moss
No relevant relationships to disclose
M. Gounder
No relevant relationships to disclose
D. C. Lindquist
No relevant relationships to disclose
J. J. Ji
No relevant relationships to disclose
A. P. Chen
No relevant relationships to disclose
M. J. Egorin
No relevant relationships to disclose
B. Kiesel
No relevant relationships to disclose
J. H. Beumer
No relevant relationships to disclose
R. S. DiPaola
No relevant relationships to disclose